 |
 |
 |
 |
 |
 |
 |
 |
-
BROWSE TOPICS IN CLINICAL MANAGEMENT:
Antiretroviral Therapy- Complications of HIV/HAART
- Research & Development
- Clinical Trials
- Quality of Life & Patient Care
Antiretroviral Therapy
When to Initiate Treatment: Research
See also: Research on Primary HIV Infection
- CROI: Could earlier ART Reduce Risk of Death from Non-AIDS Related Illnesses in People With HIV? (February 6, 2008)
From aidsmap.com - New HIV Treatment Guidelines in Europe Recommend HAART Initiation at 350 Cells/mm3 (October 25, 2007)
In aidsmap.com - Possible Benefit to Starting Treatment at High CD4 Count, Massive Study Finds (August 24, 2007)
The study of more than 17,000 treatment-naive patients found that, even among those with a CD4+ cell count well over 350, the higher the count, the less likely they were to develop an AIDS-related illness or die.
From aidsmap.com - Current Options for First-Line Treatment of HIV Infection (July 2, 2007)
Discusses Choosing Among Drug Classes , Efavirenz-Based Combinations , Ritonavir-Boosted PI-Based Regimens and Considering NRTIs.
From The Body PRO - Early, Short-Term Treatment May Slow CD4 Decline, Study Suggests (June 2007)
In AIDS - Voices Grow Louder in Support of Earlier HAART Initiation (January 12, 2007)
From aidsmap.com - Veterans Medical Affairs Researchers to Request NIH Funding for Study Examining Best Time to Start Antiretroviral Treatment (January 8, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - CD4 Percentage May Be Useful for Deciding Whether to Start HIV Treatment (January 5, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - HIV May Cause Permanent CD4+ Cell Damage in the Gut, Study Says (December 5, 2006)
In PLoS Medicine - Strategic Use of Antiretroviral Therapy: What to Use and When? (September 28, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy - Two Studies Examine Potential Benefit of Beginning ART During Acute Infection (September 1, 2006)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Optimal Timing of HAART Initiation Does Not Differ With Regimens That Include Efavirenz or Ritonavir-Boosted Protease Inhibitors (August 15, 2006)
In XVI International AIDS Conference - To Start or Not to Start? CD4 Percentage May Provide Guidance (August 29, 2005)
Among people with a CD4 count above 350, HIV disease progression is found to be 3.6 times more likely for those with a CD4 percentage below 17%.
From aidsmap.com - Tangle of Interests and Disclosure Omissions Cracks Authors' Case for Early, Aggressive Treatment (January 2005)
AIDS advocate Mike Barr expresses concern over the influence of drug company money on HIV clinical practice -- and over some journals' lax disclosure policies.
In TAGline, from Treatment Action Group - Articles Debate Starting HIV Therapy at CD4 Count Over 350 (November 23, 2004)
From aidsmap.com - Injection Drug Users Should Start HAART Earlier, Study Suggests (September 8, 2004)
From aidsmap.com - Study Supports Early Start to NNRTI-Based HAART (July 1, 2004)
A small London study finds that early treatment causes viral load to drop to levels similar to long-term HIV nonprogressors.
In Journal of AIDS - Update on the Treatment of Acute and Early HIV Infection (May 2004)
Details of a talk by Dr. Martin Markowitz of the Aaron Diamond AIDS Research Center and Dr. Bruce Walker of Harvard Medical School; includes a discussion of drug resistance transmission.
In The PRN Notebook - Adherence, not Baseline CD4 Cell Count, Linked to CD4 Cell Gain on HAART (February 25, 2004)
New support for those who feel treatment should be delayed until a patient's CD4 cell count falls near 200.
From aidsmap.com - Little Benefit Seen for Treatment During Acute Infection (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Gastrointestinal Side Effects Lead One in Eight to Change HAART Regimen in First Year of Treatment (November 27, 2003)
More than half of new HAART patients were also found to switch or stop their initial regimens within the first year, often without consulting their doctors.
From aidsmap.com - Gilead Warns Against Use of Triple-NRTI Regimen 3TC, ddI, Tenofovir (October 14, 2003)
To read PDF, click here
From U.S. Food and Drug Administration - Interim Analysis of Failure of Tenofovir/Abacavir/3TC Regimen (September 16, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - A Comparison of AZT/3TC vs. d4T/ddI, Plus Efavirenz, Nevirapine or Indinavir/Ritonavir (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - Efavirenz or Nevirapine Regimens Are More Potent Than Trizivir for Initial Therapy (September 15, 2003)
A 100-patient Spanish study confirms the findings of ACTG 5095.
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - Emergence of Resistance-Associated Mutations Over 96 Weeks in Patients Initiating ABC/3TC + d4T, EFV or APV/r (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - Kaletra "Monotherapy" Safe and Efficacious for Treatment-Naive Patients (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - No Major Renal Problems With Tenofovir Were Identified in the Naive Population Evaluated in the GS 903 Study (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - Recent Advances in the Clinical Management of the Antiretroviral-Naive Patient (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - Treatment Regimens Containing Efavirenz, Nevirapine or Kaletra Are the Most Potent Options for Patients Starting Therapy (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - Trizivir Plus Efavirenz Potent for Naive Patients With Low CD4 Counts and High Viral Loads (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - Abacavir Not Inferior to AZT in Treatment-Naive Patients (September 14, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - A Randomized Trial of 2 Different 4-Drug Antiretroviral Regimens Versus a 3-Drug Regimen, in Advanced Human Immunodeficiency Virus Disease (September 1, 2003)
Patients with advanced HIV are found to benefit the most from HAART regimens containing efavirenz (Sustiva), as opposed to regimens containing nelfinavir (Viracept) or no NNRTI at all.
In Journal of Infectious Diseases - Viread, Epivir and Ziagen Combination -- Failure in Naive Patients With a Once-Daily Regimen (September/October 2003)
Daniel S. Berger, M.D., chief investigator in study ESS30009, examines what went wrong.
To read PDF, click here
In Positively Aware, from Test Positive Aware Network - Wait Six Months After HIV Treatment Begins to Determine Prognosis, Study Says (August 29, 2003)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Early Virologic Non-Response in Patients With HIV Infection Treated With Lamivudine, Abacavir and Tenofovir (July 25, 2003)
"Dear Healthcare Provider" letter from GlaxoSmithKline.
From U.S. Food and Drug Administration - Abacavir/3TC/Tenofovir Combination Fails in Treatment-Naive Patients (July 14, 2003)
Analysis by Benjamin Young, M.D., Ph.D.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Abacavir/3TC/Tenofovir Combination Failure in Treatment-Naive Patients (July 14, 2003)
Analysis by Timothy Wilkin, M.D.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - ACTG 5095: Efavirenz-Based Regimens Outperform Triple Nucleoside Combination (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Addition of Abacavir Does Not Appreciably Enhance the Antiviral Potency of a Standard Triple-Therapy Regimen (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Another Look at Induction Maintenance Therapy (July 14, 2003)
48-week data on Trizivir and efavirenz in treatment-naive patients.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - CD4 Count at Treatment Initiation Has Decreased Over the Years (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Comparison of Once-Daily FTC Vs. Twice-Daily Abacavir in a Regimen for Drug-Naive Patients (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Efavirenz-Based HAART Outperforms a Triple Nucleoside Regimen in Clinical Practice (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - For Potency Tenofovir Equals d4T but Tenofovir Beats d4T With Less Frequent and Common Side Effects (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Forty-Eight Week Data From FTC-d4T Comparison in Treatment-Naive Patients (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - FTC Potent Within a HAART Regimen in Treatment-Naive HIV-Infected Patients With High Viral Loads (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - More Results Reported on Study 903: Tenofovir + 3TC + Efavirenz Vs. d4T + 3TC + Efavirenz (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Nevirapine- Versus Efavirenz-Containing Three-Drug Regimens (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Trizivir Often Successful in Treatment-Naive Patients; Resistance Testing Key for Failures (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Abandon Trizivir When It's Working Well? A Rebuttal (July 2003)
Emily J. Erbelding, M.D., says: Don't fix what ain't broke.
In Hopkins HIV Report - Early HAART Extends Life, Costs Less, Study Says -- Despite Cardiovascular Risks (June 11, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - The Buzz: Anatomy of a Study -- Trizivir vs. Sustiva (May/June 2003)
A closer look at ACTG 5095, which examined the use of Trizivir and efavirenz in several first-line treatment regimens.
To read PDF, click here
In Positively Aware, from Test Positive Aware Network - CROI 2003: When, and With What, to Initiate Antiretroviral Treatment (February 14, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Is HAART for Primary/Early HIV Infection Associated With Improved Outcomes After Treatment Discontinuation? (February 13, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Earlier Initiation of HAART Better Preserves Functional Immune Competence Even in Persons Who Achieve "Normal" CD4+ T-Cell Counts (July 11, 2002)
In The XIV International AIDS Conference, from The Body PRO - When to Start ARV Therapy: Where Are We Now? (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO - When to Start Antiretroviral Therapy? (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Prognosis of HIV-1 Infected Drug-Naive Patients Starting Potent Antiretroviral Therapy: Multi-Cohort Analysis of 12,040 Patients (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO - New Finding May Help Doctors Prevent HIV Drug Resistance (November 22, 2001)
From U.S. National Institute of Allergy and Infectious Diseases - When to Start Antiretroviral Therapy; Considerations in Choosing an Initial Regimen; When to Change Regimens; Options for Managing Failure (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Optimizing Available Antiretroviral Therapies (February 8, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  |
  |